Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 in Subjects With Cystic Fibrosis
Conditions
Interventions
PTI-428
Placebo
Locations
26
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Arizona
Tucson, Arizona, United States
Stanford University
Stanford, California, United States
National Jewish Health
Denver, Colorado, United States
Central Florida Pulmonary Group
Altamonte Springs, Florida, United States
Northwestern University
Chicago, Illinois, United States
Start Date
August 21, 2018
Primary Completion Date
February 18, 2019
Completion Date
February 18, 2019
Last Updated
February 27, 2020
NCT02417740
NCT06616857
NCT07108153
NCT02740868
NCT07274631
NCT07303621
Lead Sponsor
Proteostasis Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions